Myelomonocytic leukaemia following cyclophosphamide therapy of rheumatoid disease.
A 69-year-old woman treated for 31 months with daily oral cyclophosphamide for refractory rheumatoid disease developed acute myelomonocytic leukemia 21/2 years after stopping the drug. The possibility of a casual association between the therapy and subsequent leukaemia is supported by the growing experience with cytotoxic agents.
D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007951:Leukemia, Myeloid / Q000209:etiology* / Q000276:immunology
D003520:Cyclophosphamide